Dactolisib (codenamed NVP-BEZ235 and BEZ-235) is an imidazoquinoline derivative acting as a PI3K inhibitor. It also inhibits mTOR. It is being investigated as a possible cancer treatment.
It has been shown to be toxic to Waldenström's macroglobulinemia cells.
It was the first PI3K inhibitor to enter clinical trials, in 2006 (primary outcome results due in 2010).